<Suppliers Price>

Clopidogrel

Names

[ CAS No. ]:
113665-84-2

[ Name ]:
Clopidogrel

[Synonym ]:
(S)-Clopidogrel
Methyl-(2S)-(2-chlorphenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoat
thieno[3,2-c]pyridine-5(4H)-acetic acid, a-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (aS)-
Plavix
Clopilet
Clopidogrelum
(+)-Clopidogrel
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
MFCD05662337
(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester
Methyl (+)-(S)-a-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate
Clopidogrel
Methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
Zyllt
methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-

Biological Activity

[Description]:

Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> P2Y Receptor
Research Areas >> Cardiovascular Disease

[Target]

P2Y12 receptor[1].


[In Vivo]

Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis[1]. The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS[2].

[Animal admin]

Mice[1] 13-week-old C57BL/6J male mice are used throughout the study. After 1 week of acclimation, 15 mice are injected I.P. with streptozotocin (STZ) at a dosage of 55 mg/kg body weight daily for five consecutive days. Additional 15 mice as controls (Ctrl) are injected with a vehicle solution (0.1 mol/L citrate acid buffer, pH 4.3-4.5). Seven days after the last STZ administration, hyperglycemic mice (3-hour fasting blood glucose ≥250 mg/dL) are considered T1D (DM). This time point is defined as a baseline. Three months after diabetes induction, five diabetic and five control mice are sacrificed and blood and kidneys harvested. The remaining animals are divided in four groups: Normal control with vehicle (Ctrl), Normal control with Clopidogrel (Ctrl+ Clo), T1D (DM) with vehicle, and DM with Clopidogrel treatment (DM+Clo) and are treated with 20 mg/kg b.w./day Clopidogrel or with vehicle administered in their drinking water for three additional months. At the end of experiment, mice are intraperitoneally anesthetized with Avertin (tribromoethanol, 350 mg/kg) and sacrificed to collect blood and kidneys for mRNA, protein, and histological analyses[1].

[References]

[1]. Zongyu Zheng, et al. Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis. Int J Biol Sci. 2019 Jan.

[2]. An insight into the interaction between clopidogrel and proton pump inhibitors By Shah, Bhavik S.; Parmar, Sanjay A.; Mahajan, Shailaja; Mehta, Anita A. From Current Drug Metabolism (2012), 13(2),225-235.


[Related Small Molecules]

Suramin sodium | MRS 2578 | Diquafosol Tetrasodium | Prasugrel | BPTU | AZD 1283 | TAK-024

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
423.7±45.0 °C at 760 mmHg

[ Molecular Formula ]:
C16H16ClNO2S

[ Molecular Weight ]:
321.822

[ Flash Point ]:
210.0±28.7 °C

[ Exact Mass ]:
321.059021

[ PSA ]:
57.78000

[ LogP ]:
4.23

[ Vapour Pressure ]:
0.0±1.0 mmHg at 25°C

[ Index of Refraction ]:
1.617

[ Storage condition ]:
2-8℃

Safety Information

[ Hazard Codes ]:
Xn:Harmful

[ Risk Phrases ]:
R22

[ Safety Phrases ]:
S36/37-S22

[ WGK Germany ]:
3

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Related Compounds